Krilogy Financial LLC Reduces Stock Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Krilogy Financial LLC cut its stake in IDEXX by 87.5% in Q4, selling 3,543 shares and leaving it with 506 shares valued at about $353,000, according to the fund's latest 13F filing.
• Company insiders have been net sellers recently — EVP Michael G. Erickson sold 5,371 shares (~$3.37M) and EVP Nimrata Hunt sold 1,758 shares (~$1.12M), with insiders selling a total of $29.86M of stock in the past 90 days and now owning 0.79% of shares.
• Analysts have trimmed price targets but the consensus remains a Moderate Buy with a $760 average target, while IDEXX recently beat quarterly EPS expectations and set FY2026 guidance of 14.29–14.80 EPS.

Krilogy Financial LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 87.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 506 shares of the company's stock after selling 3,543 shares during the quarter. Krilogy Financial LLC's holdings in IDEXX Laboratories were worth $353,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $29,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $31,000. Salomon & Ludwin LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $35,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. Insiders own 0.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on IDXX shares. BTIG Research dropped their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. UBS Group dropped their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a report on Tuesday, February 3rd. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $760.00.

IDEXX Laboratories Stock Performance

IDXX opened at $565.93 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $427.70 and a 12-month high of $769.98. The company has a market cap of $44.95 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 3.41 and a beta of 1.72. The company's 50 day moving average is $594.81 and its 200 day moving average is $652.81. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter last year, the business earned $2.53 EPS. The firm's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.